RCKT Q2 2023 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$69M

Net Income

-$66M

EPS (Diluted)

$-0.82

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$55M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$462M

Total Liabilities

$59M

Stockholders' Equity

$403M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$69M	-$54M	-26.8%
Net Income	-$66M	-$54M	-20.8%